Medunik USA strengthens Pheburane(R) (sodium phenylbutyrate) coverage under Medicaid Programs

Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs, and part of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life ...
Washington Examiner

Urea-cycle disorder treatment reviewed

Nitrogen is a big part of the air we breathe, but too much can kill. Researchers at Johns Hopkins University reviewed 25 years of studies on using sodium phenylacetate and sodium benzoate to help ...
WDAF-TV

Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherence GENEVA, SWITZERLAND / ...
MarketWatch

Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market Landscape - Technavio

NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global urea cycle disorder treatment market size is estimated to grow by USD 215.4 million from 2024-2028, ...
Seeking Alpha

Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

A copy of the poster presentation from the 2023 SIMD Meeting is available on Acer’s website at: https://www.acertx.com/wp-content/uploads/2023/03/2023-SIMD-DCE ...
KTLA

CAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of RNA-based therapeutics designed to upregulate gene expression ...